XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:    
Net loss $ (56,582,857) $ (19,397,016)
Adjustments to reconcile net loss to net cash used in operating activities:    
Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense 10,266,023 7,863,492
Depreciation and amortization 8,978,317 5,136,159
Gain on short term investments   (24,934)
Amortization of preferred stock discount and issuance cost 2,440,241 281,211
Changes in fair value of derivative liability (2,096,904) 138,325
Write off of acquired in-process research and development 1,150,000  
(Gain) loss on disposal of assets (278,920) 1,355,972
Gain on contract termination   (656,278)
Non-cash interest expense 661,058 165,567
Contributions paid with common stock 607,363  
Bad debt expense (recovery) (97,739) (70,829)
Goodwill impairment charge 19,432,667 558,168
Deferred income taxes (688,699) (830,681)
Changes in operating assets and liabilities, net of the effect of acquisitions:    
Prepaid expenses and other current assets (786,728) (24,140)
Accounts receivable 116,789 98,505
Inventory 4,640,282 (7,469,128)
Unearned revenues 590,124 (336,704)
Other assets (2,386,544) (127,113)
Income tax payable   (667,729)
Accounts payable, accrued expenses and other current liabilities (6,892,467) 5,530,454
Net cash used in operating activities (20,927,994) (8,476,699)
Cash flows from investing activities:    
Cash received in acquisitions 320,863  
Purchase of short-term investments (28) (2,424,132)
Proceeds from short-term investments   2,742,018
Change in restricted cash used as collateral for notes payable 3,534,864 (1,045,955)
Acquisition of property and equipment (5,910,279) (16,377,722)
Net cash used in investing activities (2,054,580) (17,105,791)
Cash flows from financing activities:    
Net proceeds from the exercise of options and warrants 7,100 3,101,850
Net proceeds from issuance of capital stock 21,152,682 21,212,974
Net proceeds from issuance of preferred stock   8,894,062
Payment from related party 644,414 566,845
Repayment of mortgage loan (149,542)  
Proceeds of bank loan 20,261,900 3,000,000
Repayment of bank loan (7,829,400) (2,203,650)
Proceeds from notes payable 10,950,616 20,506,518
Repayment of notes payable (20,786,909) (21,000,225)
Repayment of debt to related party (3,531,491)  
Repayment of preferred stock (650,000)  
Payment of dividend   (222,924)
Net cash provided by financing activities 20,069,370 33,855,450
Impact of changes of foreign exchange rates 46,245 180,062
Net (decrease)/increase in cash and cash equivalents (2,866,959) 8,453,022
Cash and cash equivalents at beginning of year 15,612,391 7,159,369
Cash and cash equivalents at end of period 12,745,432 15,612,391
Cash paid during the period for:    
Interest 1,522,700 279,596
Taxes 1,119,500 2,056,250
Supplemental Schedule of non-cash investing activities    
Acquisition of property and equipment   2,443,958
Capitalized interest 384,300 391,466
Supplemental schedule of non-cash financing activities    
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock 3,511,200  
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock 748,900  
Financing costs for capital stock raises   33,355
Conversion of Convertible Redeemable Series C Preferred Stock   13,720,048
Dividend to Related Party reinvested as loan payable 11,726,100  
Amorcyte
    
Supplemental schedule of non-cash financing activities    
Common stock, warrants and contingent consideration issued with the acquisition 8,483,400  
PCT
    
Supplemental schedule of non-cash financing activities    
Common stock, warrants and contingent consideration issued with the acquisition $ 17,200,000